SOURCE: Equity Markets Inc.

October 06, 2011 09:00 ET

US Domestic, Global Economic Outlook - Equity Research on Genomic Health, Inc. and EXACT Sciences Corporation

MACAU--(Marketwire - Oct 6, 2011) - Today, announced its research report highlighting Genomic Health, Inc. (NASDAQ: GHDX) and EXACT Sciences Corporation (NASDAQ: EXAS). Full content and research is available at

Short-term outlooks within US and global economies continue to adjust downward, as US Treasury yields touched their lowest levels in over 65 years. International Monetary Fund downgraded estimates for US growth by 1.0% this year, down from 2.5%. 'Significant downside risks' to the US economy were confirmed by the Federal Reserve pressured by 'strains in global financial markets'.

As the US dollar trades above an eight-month high against the Euro, it highlights a deepening of the Eurozone sovereign debt crisis -- furthered by continued policy inaction from European governments. We expect continued volatility until economic data stabilizes and we see decisive policy action to deal with the Eurozone debt crisis.

Our members are preparing for a turn in tides. Currently, the Credit Suisse Risk Appetite Indicator is at a 30-year low. For the past three occurrences, this level has acted as a leading indicator of large stock market rallies 18 months following.

Equity Markets has reviewed Genomic Health, Inc. for its current position within the healthcare industry. Genomic Health, Inc. (Genomic Health) is a molecular diagnostics company focused on the development and global commercialization of genomic-based clinical laboratory services, which analyzes the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The full research report on Genomic Health, Inc. (NASDAQ: GHDX) is available here:

Equity Markets has reviewed EXACT Sciences Corporation for its development within the healthcare industry. Exact Sciences Corporation (Exact) is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. It has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. The full research report on EXACT Sciences Corporation (NASDAQ: EXAS) is available here:

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact Information